MRNA
Moderna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$226.89
+4.07%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$217.27
From 52W high−4.06%
Volume18.74M
Market cap$90.58B
P/E (TTM)—
P/S (TTM)40.7x
Div yield—
Key dataOct 19, 2026
Open
$217.27
From 52W high
−4.06%
Volume
18.74M
Market cap
$90.58B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−30.7x
P/E (TTM)
—
RSI (14)
63.7
MomentumView details →
1D Return
+4.07%
YTD Return
+663.00%
SummaryUpdated Jun 1, 2026
Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company founded in 2010 and headquartered in Cambridge, Massachusetts. The company went public in December 2018 and gained global prominence during the COVID-19 pandemic as one of the first companies to develop and commercialize an mRNA-based vaccine. Originally founded as Moderna Therapeutics, the company changed its name to Moderna, Inc. in August 2018. Today, Moderna has evolved from a single-product COVID vaccine company into a multi-product biotechnology firm with an expanding pipeline of mRNA-based therapeutics and vaccines across multiple disease areas.
Similar companies
Latest newsMore news →
Moderna, Inc. shares were trading higher on Monday.6h agoModerna, Inc. shares fell sharply in the morning, reaching a low of $208.96, down 11.6%, before trading near their lows; they were quoted at $214.89, down 9.14%.3d agoModerna, Inc. appointed Devin Smith as chief ethics and compliance officer and head of legal.6d ago